Key facts
- Notable investors include iAccel (Seongnam-si).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for ROOKIT
- ·The full record, as it builds
Funding rounds
No funding rounds for ROOKIT are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ROOKIT
Provider of molecular diagnostic and genetic analysis services intended to support clinical testing and disease risk evaluation. The company provides gene analysis, clinical testing products, in vitro diagnostic kits, and multi-target respiratory test kits, enabling healthcare providers and laboratories to perform faster, more accurate, and reliable diagnostic assessments.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2022
- Website
- rookit.kr/
- Ownership
- Privately Held (backing)
ROOKIT doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ROOKIT shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ROOKIT in its N-PORT filings yet. We sweep new filings monthly.